410 likes | 433 Views
Gain insights into Pre-Exposure Prophylaxis models for men and women by Dr. Robert M. Grant. Explore the complexities and controversies of HIV prevention methods, from underutilized concepts to adherence challenges. Understand the nuances between prevention and treatment approaches, drug resistance concerns, and the significance of adherence in Pre-Exposure Prophylaxis. Learn from real-world data and expert opinions to navigate the complexities of HIV prevention.
E N D
Pre-ExposureProphylaxis:How to PrEP with Models of Men and Women Robert M Grant, MD, MPH Sept 24, 2010 Maurice Cook (EM Designs Group, Inc.)
HIV Prevention • 3 new infections for every person starting ART • Few Concepts Known • Condoms, Education, Clean Needles, VCT, MTCTp, Circumcision for Heterosexual Men, Treatment • All underutilized, most controversial • Multiple Concepts Failed • Acyclovir, Diaphragms, Mass STI Treatment, Intensive Counseling, Polyanion Microbicides • No Surrogate Markers Known • Adherence can run ½ reported levels • Potential Beneficiaries • Would often rather stay in bed then “advocate” for prevention
"We are really groping in the dark" Salim S. Abdool Karim Quoted in the Washington Post, November 1, 2007
What I Heard(I may have been mistaken) • Pills are for sick people • We are not sick • HIV is one of many problems • Certainly NOT the most urgent • Violence, Poverty, Isolation are More Urgent • If you want to study us • Use our names • Studying sex workers in an era when “sex work” was a forbidden term was a non-starter
Treatment and PreventionSimilar Technology • Treatment may prevent transmission • Prevention enables treatment • Both may use pills • Indeed, the same pills • Evaluated with Randomized Clinical Trials • Intention to treat is primary
Prevention And Treatment Are Different in RespectsThat Bear Directly on Adherence
Prevention is Not Treatment:1) No Patients • Healthy people, notwithstanding… • Language That Pathologizes People • “risk groups” and “vulnerable groups” vs • gay men, transexuals, sex workers, etc • Language that Pathologizes Acts • “risk behavior” vs • Sex or work or community or procreation
Prevention is Not Treatment:2) No regimens • Treatment regimens can be optimized • In vitro activity suggest target level • Pharmacokinetics suggest dosing interval • Phase II studies narrow to few options • Phase IIb/III select the best option • Phase IV explore alternatives • Optimization Made possible by • Surrogate markers, small sample size
Prevention is Not Treatment:2) No Regimens • No surrogate markers for HIV prevention • Immune correlates not known • Minimum protective level not known • Target cells for activity not known • Safety parameters not always clear • Prevention Trials Are Large • few options evaluated
Counseling When There is No Regimen • “Adherence” to an optimized regimen • Does not apply to PrEP • In Prevention, we do not say • “Don’t use condoms unless you can use them everytime” • Also Applies to… • Communication with Partners • Use of HIV Tests • May Apply to Pill use as well.
Prevention is not Treatment3) Drug Resistance? • In treatment, the virus population has many billions of opportunities to generate resistance • partial adherence to nnRTIs/3TC allows replication to generate drug resistant mutants • Partial adherence to PIs may not be sufficient to select the drug resistant mutants. • In Prevention, the virus population clings to a few mls of genital secretions • it is unknown whether new mutations can be generated. • Starting PrEP in the window period of infection will select resistance
Daily PrEP Selected M184I/V Resistance in 2/6 Animals Wild type Resistent Not tested Garcia-Lerma et al, 2008
Absence of drug resistance in macaques failing iPrEP with oral Truvada (2 weekly doses) DM92X 1800 DM91 8 8 8 6 6 6 wt wt 4 wt Log10 RNA copies/ml 4 4 2 2 2 0 0 0 0 4 8 12 16 20 0 4 8 12 16 20 0 4 8 12 16 20 Weeks Weeks Weeks DK40 DL6V 35032 8 8 8 6 6 wt wt 6 wt Log10 RNA copies/ml 4 4 4 2 2 2 0 0 0 0 4 8 12 16 20 0 4 8 12 16 20 0 4 8 12 16 20 Weeks Weeks Weeks Wild type Not tested Garcia-Lerma et al, 2009
Adherence and Resistance Bangsberg et al 2004
Resistance and AdherenceConcerns For PrEP • Starting or Restarting PrEP • during the RNA+/Ab- window” • Expected to select resistance • Non-adherence to the daily regimen • Unclear effect on resistance • Depends on efficacy, drug levels, selection • Fear of resistance drives a high bar • People who miss doses may give up • People who miss doses when highly exposed may be told to give both up (sex and PrEP)
Prevention is Not Treatment:4) We undermine adherence in prevention These messages have been quoted back to us during qualitative research, as reasons for deferring pill use until efficacy is proven.
Prevention is Not Treatment:5) Synergies expected • Treatment Choices Are Often Exclusionary • TDF/FTC vs AZT/3TC • EFZ vs NVP • Selecting A means not selecting B • Prevention Choices Are Typically Complementary • Condom is useful for HIV/ contraception/ STIs • PrEP may protect weak vaccine responses • PrEP may attract people into STI Care
Reported Risk Behavior Declined WithOpen-LabelPost-ExposureProphylaxisand Counseling • Martin et al., AIDS 2004
Conclusion from SF: PEP and Risk Compensation • Martin et al., AIDS 2004
Air Bags and Seat Belts • Antagonisms assumed initially, but • Airbags and seat belt innovations are now motivators for purchase of new cars • Safety conscious people demand both. • Synergies Prevail
I B IMB • Specific IMB for Each Action State • People populated by multiple IMB processes • Condom use, Test Use, PrEP Use, Reporting Motivation Information Skills Behavior IMBot
I B A situated IMBot socializing with friends
I B IMBot navigating in stormy waters:poverty, violence,racism,homophobia,addiction,sexuality.
I B Oceanic View of Sex and Society • Dynamic • Complex • Unpredictable • Mysterious • Details matter little • IMBots can learn to navigate over rough seas • Rough seas are better avoided than studied
Models of Man • Herbert Simon (1916-2001) • Published 1956 • “Bounded Rationality” • Not Pathological Within Social Context • Nobel Prize 1978 • APA award 1993
Bounded Rationality and Organizational Decision-makingOrganizations. March and Simon, 1958 • Decisions Come From Where People Sit • The Social Situation Governs • Information availability • Perceptions • Motivation and goals • Learned Skills and Heuristics
I B Social view of Sexadapted from Gagnon Sexual Conduct 1973 • Sex, both desire and control, are social constructs • Some safer than others • Plans may be lost • Behavior constrained, but not determined. • Can be studied and understood
US Traditions in Sex Research • Kinsey • Biology, Narratives, Outlets • Sociological (Gagnon & Simon) • Social scripts • Shape both desire and control • National surveys • Women’s studies/LGBT studies • Development of ED Drugs • AIDS Research
On AIDS Research • John Gagnon • “None of these studies has been undertaken to understand sexual phenomena, but rather to measure risk of seroconversion and the effectiveness of prevention efforts… Such purely AIDS-driven work forces researchers to follow outbreaks of the epidemic rather than anticipate them. • Disease and Desire. 1989
In Their Communities “Let’s Communicate”
Community Based Prevention • Ecuador • Constitutional Protections for LGBT Communities • Boston • Specialized Health Care For LGBT Communities Both Highly Successful iPrEx Sites
Successful Prevention Initiatives • Condom Use in US Cities Early 1980s • “Love Carefully” Uganda 1990s • SeroPos Seroadaptive Behaviors Late 1990s • Common Characteristics • Grass Roots Initiatives • The Scripts Changed • Love Carefully • Be a rubber man • Acknowledge Sexual Goals
People Learn What They Need to Know:Will Intermittent PrEP Create a Need to Recognize Exposure and Plan for Sex? (HPTN 067)
Toward More Effective Prevention • Advocacy for Study Populations • Gay, Lesbian, Transgender • Sex workers • Drug Users • Discordant couples • Abused • Focus on Use, not Intention • Turn the Oceans into Roadmaps • Sex, society, violence, poverty • NIH NIS and CDC NCS? • Focus on Synergies, not Antagonisms
iPrEx Presentations on PrEP Pill Use • Lorena Vargas, INMENSA, Lima, Peru • Qualitative Research in Andes • Albert Liu, SF DPH • Qualitative Research in SF • Rivet Amico, U. Conn • Next Step Counseling
Many Thanks To • HPTN 067 Behavioral Working Group • Frits Von Griensven • Rivet Amico • Kata Chillag • Daniela Marks • Michael Stirrat • Andrew Forsyth • Scott Rose • Sponsors/Funders • Division of AIDS, NIMH, Gates, CDC • IPREX Pill Use Working Group • Rivet Amico • Albert Liu • Ed Wolf • Pedro Goicochea • Lorena Vargas • Vanessa McMahan • Social Approaches • Jeff McConnell • John Gagnon • David Halperin
HIV, Risk, Behavior, and Agency1st Meeting, San FranciscoJanuary 16th and 17th, 2008